JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.

What was studied

This study looked at the safety of JAK inhibitors (JAKi) in real life. People had atopic dermatitis (AD) or alopecia areata (AA). It was a single-centre study of electronic medical records. The records ran from December 2020 to June 2025. Adults were treated as in routine practice. Side events were collected after the fact. 376 adults were included.

What they found

Side events were seen with all the drugs. They were mostly mild to moderate. A mild rise in total cholesterol, weight gain and upper airway infection were most common. Stopping the drug was mainly due to loss of effect. Stops due to side events were less common and varied. One case of venous thrombo-embolism was reported. It was in a person with other clot risk factors. No major adverse heart events (MACEs) were recorded. Malignancies were also reported. Weight gain was more common in women. Menstrual changes were rare, newly described, and the leading safety reason for stopping.

What it means for patients

The paper says no safety signals for MACEs or cancer emerged. It says other metabolic events were found. These were cholesterol rise, weight gain and menstrual changes. It says ongoing real-world safety monitoring is important.

Why it is not certain yet

This was a single-centre look back at records. Routine practice is less controlled than trials. Side events were collected after the fact.

Source

JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study.

We restate facts from the source record in our own words. The original wording belongs to its publisher.